0001209191-23-058716.txt : 20231215
0001209191-23-058716.hdr.sgml : 20231215
20231215082258
ACCESSION NUMBER: 0001209191-23-058716
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231213
FILED AS OF DATE: 20231215
DATE AS OF CHANGE: 20231215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rochlin Kate
CENTRAL INDEX KEY: 0001898521
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39692
FILM NUMBER: 231488838
MAIL ADDRESS:
STREET 1: IN8BIO, INC.
STREET 2: EMPIRE STATE BUILDING, SUITE 5330
CITY: NEW YORK
STATE: NY
ZIP: 10118
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IN8BIO, INC.
CENTRAL INDEX KEY: 0001740279
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 825462585
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: EMPIRE STATE BUILDING
STREET 2: 350 5TH AVENUE, SUITE 5330
CITY: NEW YORK
STATE: NY
ZIP: 10118
BUSINESS PHONE: (646) 600-6438
MAIL ADDRESS:
STREET 1: EMPIRE STATE BUILDING
STREET 2: 350 5TH AVENUE, SUITE 5330
CITY: NEW YORK
STATE: NY
ZIP: 10118
FORMER COMPANY:
FORMER CONFORMED NAME: Incysus Therapeutics, Inc.
DATE OF NAME CHANGE: 20180510
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-13
0
0001740279
IN8BIO, INC.
INAB
0001898521
Rochlin Kate
C/O IN8BIO, INC.
350 5TH AVE. SUITE 5330
NEW YORK
NY
10118
0
1
0
0
Chief Operating Officer
0
Common Stock
2023-12-13
4
A
0
12295
A
17558
D
Series A Warrants (right to buy)
1.25
2023-12-13
4
A
0
12295
A
2025-06-13
Common Stock
12295
12295
D
Series B Warrants (right to buy)
1.50
2023-12-13
4
A
0
12295
A
2028-12-13
Common Stock
12295
12295
D
The reported securities are included within 12,295 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock.
Fully vested and exercisable.
/s/ Jason Minio, Attorney-in-Fact
2023-12-15